Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L36a (RPL36A) is a structural protein component of the large (60S) subunit of cytoplasmic ribosomes, which are responsible for the synthesis of proteins in eukaryotic cells[1][3][5]. RPL36A belongs to the L44E (L36AE) family and is highly conserved; it is distinct from but shares similarity with the ribosomal protein L36a-like (RPL36AL)[1][3][5]. RPL36A is essential for the assembly and structural integrity of the ribosome and participates in ribosomal RNA binding[3][5]. Overexpression of RPL36A has been associated with increased cell proliferation and has been observed in hepatocellular carcinoma, suggesting a possible role in tumor growth regulation and cancer biology[1][6]. There are no current drugs specifically targeting RPL36A, and it is not generally classified as a direct therapeutic target, but its expression levels may provide disease biomarker utility, especially in cancer[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L36a (RPL36A).